JP2018538273A5 - - Google Patents

Download PDF

Info

Publication number
JP2018538273A5
JP2018538273A5 JP2018526571A JP2018526571A JP2018538273A5 JP 2018538273 A5 JP2018538273 A5 JP 2018538273A5 JP 2018526571 A JP2018526571 A JP 2018526571A JP 2018526571 A JP2018526571 A JP 2018526571A JP 2018538273 A5 JP2018538273 A5 JP 2018538273A5
Authority
JP
Japan
Prior art keywords
compound
formula
combination
composition
alkoxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018526571A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018538273A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/063462 external-priority patent/WO2017091644A1/en
Publication of JP2018538273A publication Critical patent/JP2018538273A/ja
Publication of JP2018538273A5 publication Critical patent/JP2018538273A5/ja
Pending legal-status Critical Current

Links

JP2018526571A 2015-11-23 2016-11-23 虚血性脳卒中を処置するための組成物および方法 Pending JP2018538273A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562258882P 2015-11-23 2015-11-23
US62/258,882 2015-11-23
PCT/US2016/063462 WO2017091644A1 (en) 2015-11-23 2016-11-23 Compositions and methods for treating ischemic stroke

Publications (2)

Publication Number Publication Date
JP2018538273A JP2018538273A (ja) 2018-12-27
JP2018538273A5 true JP2018538273A5 (enExample) 2020-01-09

Family

ID=58764360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018526571A Pending JP2018538273A (ja) 2015-11-23 2016-11-23 虚血性脳卒中を処置するための組成物および方法

Country Status (9)

Country Link
US (2) US20180344682A1 (enExample)
EP (1) EP3380095B1 (enExample)
JP (1) JP2018538273A (enExample)
KR (1) KR20180081812A (enExample)
CN (1) CN108472275A (enExample)
AU (1) AU2016359674A1 (enExample)
CA (1) CA3005909A1 (enExample)
MX (1) MX390748B (enExample)
WO (1) WO2017091644A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US9855276B2 (en) 2012-10-25 2018-01-02 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP3506894B1 (en) * 2016-08-31 2023-08-23 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
WO2019017995A1 (en) 2017-07-20 2019-01-24 Aztherapies, Inc. FORMULATIONS OF CROMOLYNE SODIUM POWDER AND IBUPROFEN
JP2021505658A (ja) * 2017-12-04 2021-02-18 ザ ジェネラル ホスピタル コーポレイション クロモリン組成物及びその方法
CA3096545A1 (en) * 2018-04-09 2019-10-17 The General Hospital Corporation Combination therapies for the treatment of amyotropic lateral sclerosis and related disorders
JP2021529771A (ja) 2018-07-02 2021-11-04 ザ ジェネラル ホスピタル コーポレイション クロモリンナトリウムおよびα−ラクトースの粉末製剤
US12383528B2 (en) 2018-12-10 2025-08-12 The General Hospital Corporation Cromolyn esters and uses thereof
JP2023520580A (ja) 2020-04-06 2023-05-17 ザ ジェネラル ホスピタル コーポレイション コロナウイルス誘発炎症状態の処置方法
WO2022146914A1 (en) 2020-12-28 2022-07-07 The General Hospital Corporation Cromolyn derivatives and uses thereof
WO2025235823A1 (en) * 2024-05-08 2025-11-13 The Johns Hopkins University Compositions and methods for treatment of neuronal injury and neurode generative disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071531A1 (en) * 2003-02-13 2004-08-26 Licentia Oy Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
KR101414810B1 (ko) * 2004-08-30 2014-07-18 주식회사 유스팜인터내셔널 국소 허혈 모델에서의 가용화 udca의 신경보호 효과
CA2751125C (en) 2009-01-29 2017-06-20 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US9925282B2 (en) * 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
TW201613969A (en) * 2009-03-05 2016-04-16 Abbvie Inc IL-17 binding proteins
EP2406260A1 (en) * 2009-03-11 2012-01-18 Plexxikon, Inc. Pyrrolo [2, 3-b]pyridine derivatives for the inhibition of raf kinases
US9855276B2 (en) * 2012-10-25 2018-01-02 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
WO2015002703A1 (en) * 2013-05-23 2015-01-08 Aztherapies, Inc Methods for delivering cromolyn
AU2014340182B2 (en) * 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CA2938994A1 (en) * 2014-02-10 2015-08-13 Patara Pharma, LLC Inhalable formulations of sodium cromolyn with improved bioavailability
EP3506894B1 (en) * 2016-08-31 2023-08-23 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases

Similar Documents

Publication Publication Date Title
JP2019507781A5 (enExample)
JP2016534063A5 (enExample)
JP2022512482A5 (enExample)
JP2018534348A5 (enExample)
JP2016512531A5 (enExample)
JP2009530398A5 (enExample)
JP2019524883A5 (enExample)
JP2010077141A5 (enExample)
JP2020500862A5 (enExample)
JP2020097577A5 (enExample)
JP2019510039A5 (enExample)
JP2015508103A5 (enExample)
JP2013032389A5 (enExample)
JP2015078230A5 (enExample)
JP2018518537A5 (enExample)
JP2013509429A5 (enExample)
JP2017513836A5 (enExample)
JP2013542261A5 (enExample)
JP2016511753A5 (enExample)
JP2011527332A5 (enExample)
JP2012532883A5 (enExample)
JP2014500861A5 (enExample)
JP2019519587A5 (enExample)
JP2019516739A5 (enExample)
JP2015509075A5 (enExample)